Micafungin is an antimycotic drug and represents animportant addition to the available therapies for the treatmentof systemic fungal infections. Micafungin is used in the treatmentof invasive candidiasis, oesophageal and prophylaxis ofCandida infections. It inhibits, in a non-competitive way, thesynthesis of 1,3-b-D-glucan, a component of fungal cell walland is rapidly distributed into the tissues. It has a high-ratebond with respect to plasma protein; the above mentionedbond is independent from the concentration of the drug. It ismetabolized through the liver, being not subject to intensemetabolic transformations until the excretion. There is no evidenceof systemic accumulation after repeated use and thesteady-state is reached in 4-5 days. Medical records examinedat the State Hospital Pharmacy of Marsala, highlightsthat, from 01.06.2014 to 01.08.2014, in this hospital 12vials were used by the patients hospitalized in the departmentof Intensive Care: 8 patients are aged between 75 and 83and have a body weight higher than 40 kg; 3 patients areaged between 40 and 60 and have a body weight higherthan 40 kg and 1 patient has an age equal to 17 years andhas a body weight equal to 40 kg. Two patients need a doseincrease, for the others 10 patients the first dose resulted sufficient.Mycamine was used for the treatment of hypovolemicpost-operative shock. The most frequently recorded adversereactions were anaemia, hypokalaemia, hypomagnesaemia,phlebitis, nausea, liver problems. Given the different weight ofthe subjects, the dosage was different.
|Numero di pagine||2|
|Rivista||JOURNAL OF BIOLOGICAL RESEARCH|
|Stato di pubblicazione||Published - 2014|